GE HealthCare Technologies Inc. (GEHC)
Nasdaq · Chicago, Illinois, USA · Founded 2023 · CEO Peter Arduini
Valuation summary
$107.23 fair value versus $81.89 in the market, a difference of +30.9%. Rated Strong Buy.
| Fair value per share | $107.23 |
| Current share price | $81.89 |
| Upside / downside | +30.9% |
| Bear case | $62.34 |
| Bull case | $173.38 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.50% |
| Market capitalisation | $37B |
| EV / Sales | 2.0x |
About GE HealthCare Technologies Inc.
Spun off from General Electric in January 2023, though its roots in medical imaging go back over a century. Peter Arduini has been chief executive since 2022. GE HealthCare is one of the world's largest makers of medical imaging equipment — CT, MRI and molecular imaging scanners — as well as ultrasound, patient monitoring and the contrast agents and radioactive tracers used in scans.
Investment case
- A large installed base of scanners produces service revenue.
- New AI-enabled imaging and radiopharmaceuticals support growth.
- Pharmaceutical diagnostics is a high-margin, growing business.
Key risks
- China, a large market, has seen weak hospital purchasing.
- Tariffs raise costs on equipment and components.
- Hospital capital budgets are cyclical.
Recent developments
- 2026-10-28 · Q3 beats with strong organic growth and wider margins as adjusted EPS rises; full-year guidance raised source
Revenue by segment
| Imaging | 45% |
| Advanced Visualization Solutions | 23% |
| Pharmaceutical Diagnostics | 12% |
| Patient Care Solutions | 20% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $23.1B | $2.4B |
| Year 2 | $24.7B | $2.7B |
| Year 3 | $26.4B | $3.0B |
| Year 4 | $28.2B | $3.3B |
| Year 5 | $30.1B | $3.7B |
What the street says
A steady medtech since the spin-off; China and tariffs are the swing factors.
Comparable companies: BSX · IQV · MDLN · TEVA · DXCM · HCA · CI · SYK
Open the interactive model, price chart and sensitivity grid →